Navigation Links
Psychemedics Corporation Announces 2008 Year End Results
Date:2/18/2009

Declares Quarterly Dividend

ACTON, Mass., Feb. 18 /PRNewswire-FirstCall/ -- Psychemedics Corporation (Nasdaq: PMD) today announced fourth quarter and year-end financial results for the period ended December 31, 2008. The Company also announced a quarterly dividend of $0.17 per share payable to shareholders of record as of March 6, 2009 to be paid on March 20, 2009. This will be the Company's 50th consecutive quarterly dividend.

The Company's revenue for the year ended December 31, 2008 was $22,948,604, a decrease of 7% as compared to $24,568,824 for 2007. Net income for the year ended December 31, 2008 was $2,968,789 or $0.57 per share, a decrease of 34% from 2007 during which the Company earned $4,483,687 or $0.85 per share. Revenue for the fourth quarter was $4,824,016, a decrease of 18% as compared to $5,891,412 in the fourth quarter of 2007. Net income was $172,728 or $0.03 per share, down 81% from $906,817 or $0.17 per share for the same period of 2007.

Raymond C. Kubacki, Chairman and Chief Executive Officer, said, "Despite a challenging economic environment, the strength of our balance sheet and cash flow from operations provides Psychemedics with a solid foundation to withstand challenging economic downturns. In addition, our new business remains healthy. In fact, we continue to see significant opportunities for increasing new business. Our clients not only use the most rigorous and effective drug test available to screen out drug abusers, and save costs, but also to send a very important message to all their employees: that they take great pride in having a workforce with integrity and character. They have established a drug free culture and, in doing so, also have invested in a culture of integrity. We take great pride in working with our clients to meet these important goals. And these goals are
'/>"/>

SOURCE Psychemedics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Psychemedics Corporation Authorizes A 250,000 Share Stock Repurchase Program
2. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
3. NanoBio Corporation Raises $12 Million in Series B Financing
4. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Monoplace Hyperbaric Chambers
5. Newbridge Securities Corporation Forms BioVentures Division
6. Volcano Corporation Presentation at Roth Capital Partners Conference to Be Webcast
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
8. Mirixa Corporation and the APhA Foundation Finalize Partnership
9. Mach One Corporation Signs Definitive Agreement to Acquire Ceres Organic Harvest, Inc.
10. ETHEX Corporation Issues Nationwide Voluntary Recall of Products
11. Ther-Rx Corporation Issues Nationwide Voluntary Recall of Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Francisco, CA (PRWEB) , ... September 04, 2015 ... ... the delivery of product safety and pharmacovigilance services and software tools to pharmaceutical ... application, PRIMO Mobile by Allergan Japan. PRIMO Mobile is a mobile data intake ...
(Date:9/3/2015)... REDWOOD CITY, Calif. , Sept. 3, 2015 ... announced today that five abstracts highlighting the performance ... patients have been accepted for oral and poster ... of Lung Cancer,s 16th World Conference on Lung ... Cancer Center; the University of California, Davis; the ...
(Date:9/3/2015)...  StemProtein LLC, a leading manufacturer of stem ... Cell Technologies Inc., announced today that it appoints ... StemProtein. Silberg will help advance the Company,s patented ... Factors (SCFs), a significant consumer opportunity. ... biopharmaceutical industries with substantial executive level experience with ...
(Date:9/3/2015)... Michigan (PRWEB) , ... September 03, 2015 , ... ... to release its non-invasive hydration monitoring wearable early 2016. , The device, ... level using proprietary optical and electrical sensing technology. These sensors track trending ...
Breaking Biology Technology:November Research Group’s PRIMO Mobile Goes Live at Allergan Japan 2Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 2Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 3Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 4StemProtein Names Thomas H. Silberg As CEO, To Focus On Stem Cell Secreted Proteins Addresing A Variety Of Health And Beauty Related Needs 2StemProtein Names Thomas H. Silberg As CEO, To Focus On Stem Cell Secreted Proteins Addresing A Variety Of Health And Beauty Related Needs 3Technology Startup Halo Wearables to Unveil Non-Invasive Hydration Monitoring Device Early 2016 2
... (Nasdaq: AMGN ) today announced that results ... trials evaluating Vectibix® (panitumumab) in combination with chemotherapy (FOLFOX ... metastatic colorectal cancer (mCRC), respectively, were published online in ... "Both studies demonstrated that Vectibix administered with chemotherapy ...
... 4 Reportlinker.com announces that a new market ... Global Soft Tissue Allografts Industry ... report analyzes the worldwide markets for Soft Tissue ... Cartilage Allografts, Meniscus Allografts, and Tendon Allografts. The ...
... Inc., the U.S.-based group company of Shionogi & ... Drug Administration approval of the non-stimulant medication KAPVAY™ ... for the treatment of Attention Deficit Hyperactivity Disorder ... KAPVAY™ is the only formulation of clonidine hydrochloride ...
Cached Biology Technology:Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 2Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 4Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 5Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 6Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 7Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 8Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 9Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 10Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 11Reportlinker Adds Global Soft Tissue Allografts Industry 2Reportlinker Adds Global Soft Tissue Allografts Industry 3Reportlinker Adds Global Soft Tissue Allografts Industry 4Reportlinker Adds Global Soft Tissue Allografts Industry 5Reportlinker Adds Global Soft Tissue Allografts Industry 6Reportlinker Adds Global Soft Tissue Allografts Industry 7Reportlinker Adds Global Soft Tissue Allografts Industry 8Reportlinker Adds Global Soft Tissue Allografts Industry 9Reportlinker Adds Global Soft Tissue Allografts Industry 10Reportlinker Adds Global Soft Tissue Allografts Industry 11Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 2Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 3Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 4Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 5Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 6
(Date:9/2/2015)... YORK , Sept. 2, 2015 About ... concern for enterprises, banks, government organizations, telecommunication and hospitals ... assets. Keys, identity badges, and numeric keypads are used ... the structure of palm and fingers of an individual, ... Hand geometry scanners with infrared light and reflectors can ...
(Date:9/2/2015)... , Sept. 2, 2015 Security ... concern for enterprises, banks, government organizations, telecommunications, hospitals, ... numeric keypads were previously being used to prevent ... of two-factor authentication, wherein individuals could gain access ... different components, such as hardware devices and numeric ...
(Date:9/2/2015)... 2, 2015 Biometric ... in a system which uses identical human characteristic ... vein, DNA and finger print. Increasing number of ... such system which provides high level of security. ... and tokens are vulnerable to attacks. Furthermore, Biometric ...
Breaking Biology News(10 mins):Global Hand Geometry Biometrics Market 2015-2019 2Global Hand Geometry Biometrics Market 2015-2019 3Global Biometrics Spending Market in the Government Sector 2015-2019 2Global Biometrics Spending Market in the Government Sector 2015-2019 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4
... fish populations leaving them in danger of total collapse, ... measures in place to control fish stocks may not ... research, which is published in today's Nature, involved compiling ... non-exploited fish off the California coast. The research team ...
... Researchers from the University of Pennsylvania School of Veterinary Medicine ... of fish and mammals in the form of a primitive ... system. Their studies link the evolution of the adaptive ... fight infection, to the more primitive innate immunity in fish, ...
... Institut Pasteur has recently shown that the tuberculosis bacillus ... cells. This formidable pathogen is protected against even the ... may remain dormant for years. This discovery, published in ... fighting tuberculosis. Attempts to eradicate the bacillus entirely from ...
Cached Biology News:Commercial fishing causes dangerous fluctuations in fish populations 2'Killer' B cells demonstrate evolutionary link between fish and mammal immune systems 2'Killer' B cells demonstrate evolutionary link between fish and mammal immune systems 3Tuberculosis: The bacillus takes refuge in adipose cells 2
... surface is produced by a patented microwave ... giving more consistent, even cell attachment, increased ... attachment and growth uunder difficult conditions, including ... may provide a more ecominic alternative to ...
... array system, 100-240 V, uses multiplex suspension ... analysis of up to 100 proteins and ... suspension array is composed of up to ... may be conjugated with a unique reactant ...
... shaker flasks have three extra deep baffles ... to improve oxygen or gas transfer when ... long neck reduces splashing and is designed ... thickness provides the proper balance between mechanical ...
... Analysis of large numbers of samples may be ... system, which requires minimum operator attention. ... PowerStream software and interface CE 4900. The ... operates in Windows XP and Windows 98 and ...
Biology Products: